OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
· ose immunotherapeutics
AI Briefing
- OSE Immunotherapeutics to present FPR2 agonist monoclonal antibody for chronic inflammation
- Novel treatment approach for chronic inflammation
- AAI 2026 meeting
Advertisement